

1 **Title page**

2 Title: The time is ripe to harmonize global acute febrile illness etiologic investigations

3 Running title: Harmonization of acute febrile illness investigations methods

4 Article category: Brief Report

5 Author names & institutional affiliations: José Moreira^{1,2}, B. Leticia Fernando-Carballo³,

6 Camille Escadafal³, Sabine Dittrich^{3,4}, Patrícia Brasil¹, André M Siqueira¹

7 Affiliations:

8 1.Laboratório de Pesquisa Clínica em Doenças Febris Agudas, Instituto Nacional de
9 Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

10 2. Instituto Nacional de Cardiologia, Departamento de Ensino e Pesquisa, Rio de Janeiro,
11 Brazil

12 3. Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland

13 4. Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

14 Corresponding author: José Moreira MD Ph.D; e-mail: jose.moreira@ini.fiocruz.br;

15 telephone number: +55 (21) 97035-8843; Laboratório de Pesquisa Clínica em Doenças Febris

16 Agudas, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Av.

17 Brasil, 4365 – Manguinhos, Rio de Janeiro, Brazil, CEP: 21040-360; Twitter: @j_moreira_

18

19

20

21

22

23

24

25

26 **Abstract**

27 We investigated the impact of considering different case definitions of fever as inclusion criteria
28 among participants enrolling in an acute febrile illness investigation and observed that adopting a
29 subjective assessment of fever regardless of specific fever cut-off value accounted for the
30 diversity of clinical fever phenotypes and did not mischaracterize the febrile population.

31 **Keywords:** Antipyretic therapy; Fever; Acute febrile illness; Dipyrrone; Methodology

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50 **Text**

51 **Introduction**

52 Acute febrile illness (AFI) is a common reason for people seeking care and represents a range
53 of infectious and non-infectious diseases, with wide variation by region of the globe [1]. AFI
54 investigations aim to provide national and subregional epidemiology and infectious diseases
55 surveillance and to inform treatment guidelines about empirical and pathogen-specific
56 management algorithms to prioritize interventions and funding. Several AFI investigations
57 have been conducted primarily in Southeast Asia, with few global initiatives in resource-
58 constrained countries [2]. However, there is no standardized approach to conducting such
59 studies, limiting the interpretation and comparability of study findings.

60 We were involved in a multinational project around fever host-biomarkers [3] and aimed to
61 conduct a pilot study to inform the best criteria for our study site selection. We hypothesized
62 that adopting a subjective or self-reported fever assessment as part of our inclusion criteria
63 would increase the sensitivity threshold for a broad array of febrile clinical phenotypes rather
64 than specifying a cut-off value for fever at presentation. Another hypothesis was that the
65 recent antipyretic intake – largely available over-the-counter- would lower body temperature
66 at arrival at the Emergency Departments (EDs).

67 **Methods**

68 We did a cross-sectional, study of patients presenting to two urban EDs (Unidade de Pronto
69 Atendimento Manguinhos & Unidade de Pronto Atendimento Rocha Miranda) in Rio de
70 Janeiro, Brazil, between October 28, 2018, and March 29, 2019. The study was conducted
71 following the Declaration of Helsinki and the Brazilian National Ethics Research Committee
72 and was approved in August 2018 (IRB approval no:70984617.9.0000.5262). We screened
73 all consecutive non-severe patients who presented to the EDs over the study period and
74 included those who reported fever ≤ 7 days regardless of temperature measured at the EDs.

75 Research assistants prospectively collected detailed information and interviewed participants
76 or the primary caregivers to obtain data about the demographics, main chief complaint, vital
77 signs, history of fever, peak measured temperature before arrival at the EDs (temperature
78 maximum), the measured axillary temperature at the EDs, home administration of
79 antipyretics, type/dose/timing of last administration, and tests performed at the EDs.
80 Discharge diagnosis and treatment received after discharge was retrospectively collected by
81 reviewing electronic medical records. The attending physician proposed the discharge
82 diagnosis (not involved in the study), and its appropriateness was not re-evaluated. We used
83 the following definitions: fever was subjectively identified by the participant at arrival at the
84 EDs; antipyretics are mostly over-the-counter drugs that act on reducing body temperature
85 usually with added analgesic effect, and were self-administered by the participants before
86 seeking emergency care; adults those aged ≥ 18 years at recruitment, and non-severe AFI was
87 an illness that was codified as blue or green according to the Manchester Triage System at
88 EDs, which does not require hospital admission. We measured the axillary temperature at
89 triage and estimated the magnitude of defervescence, considering the highest measured self-
90 reported temperature before EDs arrival (T_{max}). Suspected infection was defined as the
91 initiation of any antimicrobial after an EDs visit.

92 **Statistical analysis**

93 Descriptive analysis was performed to characterize the distributions of several variables. A
94 Chi-square test was used to compare categorical variables between study groups. Continuous
95 variables were compared between the study groups using analysis of variance or the Kruskal-
96 Wallis test if those were found to be normally or non-normally distributed, respectively. We
97 dealt with missing data using the listwise deletion method (or complete case analysis).

98 A logistic regression model was performed to ascertain the effects of recent antipyretic
99 uptake on the likelihood that participants have an overt fever at EDs admission (i.e., ≥ 37.5

100 °C). A 2-sided *p-value* less than 0.05 was considered statistically significant. All statistical
101 analyses were performed using SPSS software (version 26, IBM, Chicago, Illinois, USA) and
102 Tableau Desktop (version 2020.4.2, Tableau, Seattle, Washington, USA). The primary
103 outcome was to investigate the impact of considering different case definitions of fever as
104 inclusion criteria among febrile patients attending EDs.

105 **Results**

106 During the study period, we triaged 1551 subjects, and 374 [24.1% (95% CI 22-26)] had a
107 history of fever at arrival at the ED, corresponding to a cumulative incidence of fever at EDs
108 of 24 per 100 triaged patients over the five months. These 374 febrile patients constitute our
109 study population, of whom 248 (66.3%), 115 (30.7%), and 11 (2.9%) had a temperature <
110 37.5 °C, ≥ 37.5 °C, and no temperature measurement registered at arrival, respectively. The
111 mean age was 30.6 [range: 0-84] years, adults (82.5%) and females (54.8%) predominated
112 (Table). The median peak measured temperature before arrival at the ED was 38.8°C (38.0-
113 39.0), and the median duration of fever was 1 [1-3] days.

114 Hundred ninety-eight febrile patients had a diagnosis of infection, with upper respiratory tract
115 infection (42.4%) followed by undifferentiated febrile illness (15.7%) and urinary tract
116 infection (14.6%) were the primary febrile syndromes (Supplementary Figure 1). Hundred
117 thirty-one patients were prescribed any antibiotic after EDs visit, which beta-lactams (73/131,
118 55.7%), quinolones (23/131, 17.5%) and macrolides (16/131,12.2%) were the classes most
119 commonly prescribed. Patients who had temperature ≥ 37.5 °C at presentation were more
120 likely to be diagnosed with an infection [76 (66%) vs. 116 (47%), crude OR: 2.2 (95% 1.4-
121 3.5) and were prescribed antibiotic most frequently compared to those with temperature <
122 37.5 °C [54 (65%) vs. 75 (48%), crude OR: 2 (95% 1.1-3.5)].

123 The site of infection varied by the height of temperature mensurated at arrival at EDs
124 ($p<0.001$). Patients who had a temperature < 37.5 °C at presentation were more likely to be

125 diagnosed with upper respiratory (31.6%) and urinary infections (15.4%) (Supplementary
126 Figure 3). The most frequently etiology diagnostics recorded in those with temperature <
127 37.5 °C at presentation were acute pharyngitis (20/248, 8%), followed by community-
128 acquired gastroenteritis (19/248, 7.6%), uncomplicated urinary tract infection (16/248,
129 6.4%), cutaneous abscess (14/248, 5.6%), and community-acquired pneumonia (9/248,
130 3.6%).

131 In total, 249/374 (66.6% (95% 61.5-71.3)) subjects reported self-administering an
132 antipyretic at home within a median of 2h [IQR 2-6] before EDs admission (24.1% of the
133 febrile subjects did not recall prior antipyretics intake). Dipyron (72.2%) was the antipyretic
134 drug most frequently administered, followed by acetaminophen (14.3%) and ibuprofen
135 (6.3%). Most antipyretic takers consumed one class (85.9%), and the median number of
136 doses taken was 2 [IQR 1-3]. Of these 249 subjects, 167/249 (67%) reported the last dose
137 administered at a mean of 2 [2-5] hours before hospital presentation. Subjects who were
138 treated with an antipyretic drug before arrival did not differ from untreated ones regarding the
139 temperature at arrival at the ED visit (37 ± 0.99 vs. 36.8 ± 0.86 , $p = 0.20$) or the documented
140 Tmax before the ED arrival (38.8 ± 0.79 vs. 38.4 ± 0.60 , $p = 0.29$).

141 The logistic regression model correctly classified 69.1% of the cases (Supplementary Table
142 1). Males were 2.2 times more likely to exhibit overt fever at presentation than females [aOR:
143 2.25, 95% CI: 1.19-4.25]. Recent antipyretic intake did not influence the pattern of fever at
144 presentation [aOR:0.81, 95% CI:0.34-1.97].

145 **Discussion**

146 Our study suggests that considering a subjective/self-reported fever as an inclusion criterion
147 rather than a specific fever cut-off value (i.e., ≥ 37.5 °C) at presentation for AFI etiologic
148 investigation results in a more inclusive study population and account for the diversity of
149 clinical fever phenotypes that are usually seen in clinical practice. Specifically, sixty-six

150 percent of our cohort would not have been included if we restricted our inclusion criteria to a
151 specific febrile cut-off, potentially impacting study recruitment and patient characterization.
152 Almost half (47.8%) of febrile participants with temperature < 37.5 °C at presentation were
153 prescribed at least one antibiotic, and their infections were mainly upper respiratory,
154 justifying their inclusion in AFI studies. Next, our findings suggest that the ubiquitous
155 administration of antipyretics (66.6%) observed in our setting did not influence the febrile
156 presentation of patients attending the EDs evaluated.

157 We concur with others [2, 4] and argue that there is an urgent need to standardize AFI study
158 protocols to make sure that we can compare results from different studies and pool their
159 results to develop national, regional, or global burden of fever estimates. Such consensus in
160 AFI research would allow better comparisons, translate evidence to practice, and inform
161 treatment policy. A harmonized definition of fever would enable a more robust and consistent
162 capture of different clinical phenotypes, including those conditions where overt fever occurs
163 inconsistently, such as upper respiratory infections and uncomplicated urinary infections.
164 Others [2] have suggested an adapted STRENGTHENING the reporting of OBSERVATIONAL studies
165 in Epidemiology (STROBE) checklist for conducting and reporting AFI research.

166 In conclusion, we suggest harmonizing the case definition of fever in AFI research for a
167 history of fever regardless of temperature cut-off would enable a complete picture of the
168 different clinical fever phenotypes, thus improving our understanding of the global burden of
169 febrile illness.

170 **Author contributions**

171 JM: writing original draft, visualization, conceptualization. BC: Review and editing. CE:
172 Review and editing. SD: review, editing. PB: conceptualization, writing, editing, supervision.
173 AS: conceptualization, writing, editing, supervision

174 **Funding**

175 The Biomarker for Fever-Diagnostic (BFF-Dx) study was funded by the Dutch, Australian,
176 and UK governments.

177 **Transparency declaration**

178 The authors have no conflict of interest to declare.

179

180 **References**

181 1. Moreira J, Bressan CS, Brasil P, Siqueira AM. Epidemiology of acute febrile illness
182 in Latin America. *Clin Microbiol Infect.* 2018; 24(8):827-835.

183 2. Rhee C, Kharod GA, Schaad N et al. Global knowledge gaps in acute febrile illness
184 etiologic investigations: a scoping review. *PLoS Negl Trop Dis.* 2019; 13(11):
185 e0007792.

186 3. Escadafal C, Geis S, Siqueira AM, et al. Bacterial versus non-bacterial infections: a
187 methodology to support use-case-driven product development of diagnostics. *BMJ*
188 *Glob Health.* 2020; 5(10)e:003141.2.

189 4. Newton PN, Guerin PJ. Febrile illness mapping-much of the world without data and
190 without evidence-based treatments. *BMC Med.* 2010; 18(1):287.

191

192 **Supplementary Tables**

193 Supplementary Table 1. Prediction model for the likelihood of overt fever at presentation in
194 374 febrile patients attending emergency departments in Rio de Janeiro, Brazil, October
195 2018 – March 2019.

196 Supplementary Table 2. Diagnosis, febrile syndrome, and antibiotic prescription in febrile
197 patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March
198 2019

199 **Supplementary Figures**

200 Supplementary Figure 1. Antibiotic class according to the foci of infection in febrile patients
201 attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019

202 Supplementary Figure 2. Variability in antibiotic prescription accordingly to the foci of
203 infection in febrile patients attending Emergency departments in Rio de Janeiro, Brazil,
204 October 2018-March 2019

205 Supplementary Figure 3. Foci of infection according to the height of temperature
206 mensurated at arrival in febrile patients attending Emergency departments in Rio de
207 Janeiro, Brazil, October 2018-March 2019

208 Supplementary Figure 4. Antibiotic class according to the height of temperature mensurated
209 at arrival in febrile patients attending Emergency departments in Rio de Janeiro, Brazil,
210 October 2018-March 2019

211

212

213

214

215

216

217

218

219

220

221

222 Table. Baseline characteristics according to the height of temperature mensurated at arrival
 223 in febrile patients attending emergency departments in Rio de Janeiro, Brazil, October 2018-
 224 March 2019
 225

	Total febrile population	History of fever but temperature < 37.5 °C	History of fever and temperature ≥ 37.5 °C	p-value
	N= 374	N= 248	N= 115	
Characteristics				
Demographics				
Age (years), mean (±SD)	31 (16)	32 (15)	28 (16)	0.02
Missing	3 (0.8)			
Male, n- (%)	169 (45.2)	103 (41.5)	62 (53.9)	0.02
Temp at arrival, (°C), mean (±SD)	37.08 (0.9)	36.55 (0.5)	38.24 (0.6)	<0.01
Missing	12 (3.2)			
Tmax (°C), mean (±SD)	38.7 (0.7)	38.7 (0.69)	38.95(0.9)	0.12
Missing	268 (71.7)			
Days of fever, mean (±SD)	1.58 (17.4)	1.45 (21.2)	1.80 (3.2)	0.86
Missing	81 (21.7)			
Degree of defervescence from Tmax, mean (±SD)	1.70 (1.13)	2.16 (0.86)	0.78 (1.04)	<0.01
Diagnosis and management				
Diagnostic testing – n (%)	76 (30.2)	42 (26.1)	32 (38.1)	0.05
Recent antibiotic use – n (%)	21 (12.2)	11 (9.6)	10 (18.9)	0.09
Missing	202 (54)			
Recent antipyretic use – n (%)	249 (66.6)	169 (87.1)	76 (90.5)	0.42
Missing	90 (24.1)			
Antibiotic prescription – n (%)	131 (53.0)	75 (47.8)	54 (65.1)	0.01

226 SD means standard deviation; Tmax higher temperature self-recorded at home before
 227 emergency department visit; Recent antibiotic use was defined as any antibiotic for
 228 systemic use started prior to emergency department visit. We excluded antibiotics for
 229 systemic use that could also be used for the treatment of tuberculosis in patients with active
 230 disease; Recent antipyretic was the use of any over-the counter antipyretic prior to
 231 emergency department visit.

232 **Key messages**

- 233 • Fever is a common reason to seek care in patients attending urban Emergency
234 Departments in Rio de Janeiro, Brazil
- 235 • Suspicion of infection is the underlying cause of fever in 53% of the febrile subjects,
236 and the respiratory source is the main focus of infection
- 237 • The use of antipyretics among febrile patients attending urban Emergency
238 Departments in Rio de Janeiro is ubiquitous, and dipyrone is the antipyretic of choice
239 in our population. However, such use did not influence overt fever presentation in
240 Emergency Departments
- 241 • Our findings are essential for designing fever etiology and question the value of
242 adopting a specific temperature cut-off for fever at enrollment, as in many fever
243 studies. We believe that a history of fever as part of the inclusion criteria is a good
244 surrogate of unwellness and might be incorporated systematically in future fever
245 studies.

246

247

248

Appendix Table of Contents

This supplementary material has been provided by the authors to give readers additional information about their work.

Supplementary Tables


- Supplementary Table 1. Prediction model for the likelihood of overt fever at presentation in 374 febrile patients attending emergency departments in Rio de Janeiro, Brazil, October 2018 – March 2019.
- Supplementary Table 2. Diagnosis, febrile syndrome, and antibiotic prescription in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019
-

Supplementary Figures

- Supplementary Figure 1. Antibiotic class according to the foci of infection in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019
- Supplementary Figure 2. Variability in antibiotic prescription accordingly to the foci of infection in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019
- Supplementary Figure 3. Foci of infection according to the height of temperature mensurated at arrival in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019
- Supplementary Figure 4. Antibiotic class according to the height of temperature mensurated at arrival in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019

Supplementary Figure 1. Antibiotic class according to the foci of infection in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019


Antibiotic class accordingly to the foci of infection in febrile patients attending ED in Rio de Janeiro, Brazil, October 2018 - March 2019



AUI stands for acute undifferentiated febrile illness; LRTI lower respiratory tract infection; SSTI skin and soft tissue infection; URTI upper respiratory tract infection; and UTI urinary tract infection


Supplementary Figure 2. Variability in antibiotic prescription according to the foci of infection in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019

Variability in antibiotic prescription accordingly to the foci of infection in febrile patients attending ED in Rio de Janeiro, Brazil, October 2018 - March 2019




AEFI stands for acute undifferentiated febrile illness; LRTI lower respiratory tract infection; SSTI skin and soft tissue infection; URTI upper respiratory tract infection; and UTI urinary tract infection

Supplementary Figure 3. Foci of infection according to the height of temperature mensurated at arrival in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019



AUI stands for acute undifferentiated febrile illness; LRTI lower respiratory tract infection; SSTI skin and soft tissue infection; URTI upper respiratory tract infection; and UTI urinary tract infection

Supplementary Figure 4. Antibiotic class according to the height of temperature mensurated at arrival in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019



Supplementary Table 1. Prediction model for the likelihood of overt fever at presentation in 374 febrile patients attending emergency departments in Rio de Janeiro, Brazil, October 2018 – March 2019.

Variable		Adjusted Odds Ratio (95% CI)	p-value
Sex	Female	-	
	Male	2.25 (1.19-4.25)	0.01
Recent antipyretic use [§]	No	-	
	Yes	0.81 (0.34-1.97)	0.65
Age (years)		0.98 (0.95-1.00)	0.10
Time from fever onset (days)		1.00 (0.98-1.01)	0.97
Baseline Heart rate (beats/min)		1.050 (1.03-1.07)	< 0.05

§Non-prescription antipyretic uptake reported by the participant before emergency department care

Dependent variable: proportion of febrile subjects with measured axillary temperature ≥ 37.5 °C at presentation

Supplementary Table 2. Diagnosis, febrile syndrome, and antibiotic prescription in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019

Presumed diagnosis by febrile syndrome	Number of presentations n/N (%)	Number of patients receiving an antibiotic prescription n/N (%)
Gastrointestinal		
Gastroenteritis	16/17 (94.11)	7/16 (43.75)
Gastritis	1/17 (5.88)	1/1 (100)
Upper respiratory tract infection		
Acute tonsillitis	34/84 (40.47)	34/34 (100)
Acute pharyngitis	22/84 (26.19)	5/22 (22.72)
Acute sinusitis	8/84 (9.52)	6/8 (75)
Common cold	5/84 (5.95)	0/5 (0)
Other upper respiratory tract infections	15/84 (17.85)	9/15 (60)
Lower respiratory tract infection		
Acute bronchitis and COPD exacerbations	3/17 (17.64)	2/3 (66.66)
Community-acquired pneumonia	9/17 (52.94)	8/9 (88.88)
Influenza	2/17 (11.76)	0/2 (0)
Other lower respiratory tract infections	3/17 (17.64)	3/3 (100)
Skin and soft tissue infection		
Cellulitis and abscesses	14/19 (73.68)	14/14 (100)
Other infection of the skin and soft tissue	4/19 (21.05)	4/4 (100)
Bacterial skin infection	1/19 (5.26)	1/1 (100)
Urinary tract infection		
Uncomplicated cystitis & pyelonephritis	28/29 (96.55)	25/28 (89.28)
Other urinary infection	1/29 (3.44)	1/1 (100)
Acute undifferentiated febrile illness		
Arboviruses	5/30 (16.66)	0/5 (0)
Unspecified febrile illness	6/30 (20)	4/6 (66.66)
Leptospirosis	2/30 (6.66)	2/2 (100)
Unspecified viral infection	15/30 (50)	1/15 (6.66)
Other	1/30 (3.33)	1/1 (100)

COPD stands for chronic obstructive pulmonary disease

